Abstract
Renal anemia is seen in 30 〜 65% of cats with chronic kidney disease (CKD). Renal anemia has been identified as independent risk factor for progression of CKD. Therefore, treatment of renal anemia have important implications in cats with CKD. The use of erythropoiesis stimulating agents (ESA) is recommended in treatment of renal anemia. ESA improve quality of life and metabolic function in cats with CKD. However, the use of ESA can create a number of complications, such as iron deficiency, thromboembolism, hypertension and pure red cell aplasia (PRCA).
